Bio-Techne Corp (TECH) has consistently made news in the biotech market, with several investment firms like
Bleakley Financial Group and
Janney Montgomery Scott LLC increasing their stakes in the company. Despite facing headwinds in Q1, the company's stocks show a
8.6% CAGR, outperforming its earnings growth in the same period. The company also announced dividends and scheduled a conference call on August 7, 2024, to share Q4 and fiscal 2024 financial results. Significant partnerships and acquisitions like the investment in
Wilson Wolf and acquisition of
Asuragen and Lunaphore indicate a robust growth strategy. The company continues to innovate, as seen in the release of their
MauriceFlex™ system and RNAscope technology, both receiving significant recognition in the biotech field. However, some analysts have decreased their EPS estimates for Q1 2025. The appointment of
Kim Kelderman as the new CEO, along with several board expansions and strategic director appointments, is expected to invigorate the company's leadership.
Bio-Techne Corp TECH News Analytics from Thu, 01 Oct 2020 07:00:00 GMT to Sun, 21 Jul 2024 13:54:04 GMT -
Rating 6
- Innovation 8
- Information 7
- Rumor -3
